{"entity":{"id":"brian-rini","kind":"person","name":"Brian I. Rini","aka":[],"tldr":"Led KEYNOTE-426, which made pembrolizumab plus axitinib a first-line standard for kidney cancer.","summary":"Brian Rini was principal investigator of KEYNOTE-426, the trial showing pembrolizumab plus axitinib improves survival over sunitinib in first-line advanced renal cell carcinoma, and of IMmotion151 (atezolizumab plus bevacizumab). He has led studies of active surveillance in metastatic RCC and of biomarkers of immunotherapy response. He directs clinical trials at Vanderbilt-Ingram.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rini%20BI%5BAuthor%5D%20renal%20pembrolizumab%20axitinib"}],"tags":["rcc","immunotherapy","trialist"],"related":[],"cancers":["rcc"],"sections":[],"technologies":["checkpoint-inhibitor","antiangiogenic"],"targets":["pd1","vegf"],"drugs":["pembrolizumab"],"companies":[],"institutions":["vanderbilt-ingram"],"pathways":[],"terms":[],"trials":["keynote-426"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief of Clinical Trials, Vanderbilt-Ingram Cancer Center; Ingram Professor of Cancer Research","institutionId":"vanderbilt-ingram","specialisms":["Renal cell carcinoma","Immunotherapy combinations","Antiangiogenic therapy","Trial design"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rini%20BI%5BAuthor%5D%20renal%20pembrolizumab%20axitinib"}],"papers":[{"title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma (KEYNOTE-426)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1816714"},{"title":"Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial","journal":"Lancet Oncology","year":2016,"doi":"10.1016/S1470-2045(16)30196-6"}],"orcid":"0000-0002-2212-080X"},"route":"/people/brian-rini/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"vanderbilt-ingram","kind":"institution","name":"Vanderbilt-Ingram Cancer Center","route":"/institutions/vanderbilt-ingram/"}],"trial":[{"id":"keynote-426","kind":"trial","name":"KEYNOTE-426","route":"/trials/keynote-426/"}]}}